BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts

By Lucas Aimee L.   Frado Laura E.   Hwang Caroline   Kumar Sheila   Khanna Lauren G.   Levinson Elana J.   Chabot John A.   Chung Wendy K.   Frucht Harold  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1960-1967

Blackwell Publishing

Access to resources Recommend Favorite

BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer

By Sakamoto Ikuko   Hirotsu Yosuke   Nakagomi Hiroshi   Ouchi Hidetaka   Ikegami Atsushi   Teramoto Katsuhiro   Amemiya Kenji   Mochizuki Hitoshi   Omata Masao  

Cancer, Vol. 122, Iss. 1, 2016-01 ,pp. : 84-90

Blackwell Publishing

Access to resources Recommend Favorite

Retrometabolic Approach for Designing Personalized Anti- Cancer Drug Molecules for Controlling Breast Cancer Resulted by BRCA1 Mutations

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 14, Iss. 1, 2017-01 ,pp. : 56-64

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives

By  

Current Cancer Drug Targets, Vol. 15, Iss. 3, 2015-05 ,pp. : 256-269

Bentham Science Publishers

Access to resources Recommend Favorite

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel

By Tung Nadine   Battelli Chiara   Allen Brian   Kaldate Rajesh   Bhatnagar Satish   Bowles Karla   Timms Kirsten   Garber Judy E.   Herold Christina   Ellisen Leif   Krejdovsky Jill   DeLeonardis Kim   Sedgwick Kristin   Soltis Kathleen   Roa Benjamin   Wenstrup Richard J.   Hartman Anne-Renee  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 25-33

Blackwell Publishing

Access to resources Recommend Favorite